NEW YORK, May 27 /PRNewswire-FirstCall/ -- Inyx, Inc. (OTC Bulletin Board:
IYXI), an emerging specialty pharmaceutical company with a focus on niche drug
delivery technologies and products, announced today that Ulrich Bartke, Ph.D.
will be joining the company on June 1, 2004 in the newly established, senior
management position of Vice President Global Sales & Marketing.
"We are very pleased to have a person with Mr. Bartke's extensive and
highly successful pharmaceutical business experience join Inyx," said Dr. Jack
Kachkar, Inyx Chairman & CEO. "Mr. Bartke's appointment is part of Inyx's
evolution into an integrated specialty pharmaceutical company. Through his
direction and initiatives, Inyx's sales and marketing efforts should be
"Initially, Mr. Bartke will focus on building Inyx's contract
manufacturing revenues and increasing the utilization of production capacity,
with the objective to increase sales and profitability," Dr. Kachkar informed.
"Additionally, he will be cultivating strategic marketing relationships with
key clients to handle the distribution of Inyx's own proprietary products,
which we are now developing and plan to start to introduce in early 2005."
"I am very pleased to be joining Inyx," said Mr. Bartke. "Inyx has niche
aerosol pharmaceutical development and production expertise that is needed in
the marketplace today, particularly the proven ability to develop and produce
non-ozone-depleting aerosol products. I am looking forward to assisting in
the growth of Inyx's business."
Mr. Bartke will be based initially at the company's development and
production center located in Cheshire, England, operated under its wholly
owned subsidiary INyX Pharma Limited. He will be directing the company's
sales and marketing activities around the world, including in North America,
Latin and South America and Asia as well as Europe.
Ulrich Bartke, Ph.D.
From 2001 to 2003, Mr. Bartke served as Vice President Global Sales &
Marketing of PowderJect Pharmaceuticals Plc, where he directed sales growth
from approximately $40 million to in excess of $290 million during his two-
year tenure. In June 2003, PowderJect, at the time a publicly owned company
traded on the London Stock Exchange, was acquired by Chiron Corporation.
Following this acquisition, Mr. Bartke became a consultant to the
pharmaceutical industry, focusing on U.S. and European markets.
Mr. Bartke began his professional career and served for 17 years, from
1984 to 2001, with GlaxoSmithKline companies in a number of different
executive capacities. He started out in manufacturing management positions
before moving into several marketing directorships at SmithKline Beecham
Pharmaceuticals. In his last position, he served as Therapy Area Director,
Vaccines, for GSK Pharmaceuticals Europe.
Mr. Bartke holds a BSc in Pharmacy and a Ph.D. in Pharmaceutical Chemistry
from the University of Berlin.
Inyx, Inc. is an emerging specialty pharmaceutical company with niche
aerosol drug delivery technologies and products. Inyx focuses its expertise
on contract manufacturing of prescription and over-the-counter pharmaceutical
products, and provides specialty pharmaceutical development and production
consulting services to the international healthcare market. In addition, Inyx
is developing its own proprietary products to be marketed by selected clients
and strategic partners. The company's operations are conducted through its
wholly owned subsidiary, INyX Pharma Limited, with a focus on niche products
and technologies for the treatment of respiratory, allergy, dermatological and
topical conditions. INyX Pharma's client base comprises large ethical
pharmaceutical corporations, branded generic companies and biotechnology
firms. The company develops and manufactures for a majority of global
markets, including: North America, Europe, Latin America and the Middle East.
INyX Pharma's R&D and production facilities are in Runcorn, near Manchester,
England. Another wholly owned subsidiary, Inyx Canada, Inc. based in Toronto,
provides business development and support services. Inyx, Inc.'s corporate
offices are in New York City.
Statements about the Company's future expectations, including future
revenues and earnings, and all other statements in this press release other
than historical facts, are "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934, and as that term is defined in the Private Securities
Litigation Reform Act of 1995. The Company intends that such forward-looking
statements be subject to the safe harbors created thereby. Since these
statements involve risks and uncertainties and are subject to change at any
time, the Company's actual results could differ materially from expected
For more information, please contact:
Jay M. Green, Executive VP
SOURCE Inyx, Inc.